<?xml version="1.0" encoding="UTF-8"?>
<p>Unlike the decisions of the US and Italian governments to use a compulsory license for their own interests, Canada, the first country to amend its domestic intellectual property laws according to the 2003 General Council’s decision on the TRIPS Agreement, used the compulsory license for the purpose of helping people in developing countries to obtain urgently needed medicines. Canada’s Access to Medicines Regime (CAMR) was drafted in May 2004 and became effective in May 2005 [
 <xref ref-type="bibr" rid="CR24">24</xref>]. CAMR requested the generic drug producer first negotiate voluntary licensing from the patent holder before issuing the compulsory license. After failed negotiation with GlaxoSmithKline and Boehringer Ingelheim, for a voluntary license and with petition from Rwanda to the World Trade Organization, Canada granted the Apotex company a compulsory license for TriAvir in [
 <xref ref-type="bibr" rid="CR25">25</xref>] to be exported to Rwanda [
 <xref ref-type="bibr" rid="CR26">26</xref>].
</p>
